Johnson & Johnson unit Janssen Biotech, a licensee of Genmab, has submitted to the FDA a marketing application to seek approval for a Darzalex, or daratumumab, formulation to be administered subcutaneously in patients with multiple myeloma. An intravenous formulation was previously approved by the FDA in November 2015.
Janssen seeks FDA approval for subcutaneous daratumumab formulation
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.